Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
Authors
Keywords
-
Journal
LIVER TRANSPLANTATION
Volume 18, Issue 9, Pages 1093-1099
Publisher
Wiley
Online
2012-04-25
DOI
10.1002/lt.23460
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prophylaxis, Preemption and Drug Resistance in CMV Infection: Too Little, Too Much or Just Right?
- (2011) J. A. Fishman AMERICAN JOURNAL OF TRANSPLANTATION
- High Incidence of Anticytomegalovirus Drug Resistance Among D+R− Kidney Transplant Recipients Receiving Preemptive Therapy
- (2011) L. Couzi et al. AMERICAN JOURNAL OF TRANSPLANTATION
- GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients
- (2011) Julian Torre-Cisneros et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
- (2011) A.A. Boudreault et al. Transplant Infectious Disease
- Therapeutic Effect of the Acquisition of Cytomegalovirus-Specific Immune Response During Preemptive Treatment
- (2011) Omar J. BenMarzouk-Hidalgo et al. TRANSPLANTATION
- Unraveling the Biologic Basis of Late-Onset Cytomegalovirus Disease in High-Risk Organ Transplant Recipients
- (2011) Nina Singh TRANSPLANTATION
- IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis
- (2010) A. C. Kalil et al. AMERICAN JOURNAL OF TRANSPLANTATION
- The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
- (2010) A. Humar et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients
- (2010) Hsin-Yun Sun et al. TRANSPLANT IMMUNOLOGY
- Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
- (2010) Atul Humar et al. TRANSPLANTATION
- International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
- (2010) Camille N. Kotton et al. TRANSPLANTATION
- Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
- (2009) D. Kumar et al. AMERICAN JOURNAL OF TRANSPLANTATION
- A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R−) solid organ transplant recipients
- (2009) R. San Juan et al. CLINICAL TRANSPLANTATION
- Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review
- (2008) H-Y. Sun et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial
- (2008) V. Kliem et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients
- (2008) O. Len et al. CLINICAL INFECTIOUS DISEASES
- Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts
- (2008) Nina Singh et al. LIVER TRANSPLANTATION
- Cytomegalovirus infection after liver transplantation: Current concepts and challenges
- (2008) Raymund-Rabe Razonable WORLD JOURNAL OF GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started